What's the need?
Prostate cancer is the most common male cancer and recently became the most commonly diagnosed cancer in England.
We urgently need to develop new and effective treatments for advanced prostate cancer, and to make sure that all patients have the information they need to make the right choices for them.
Globally, the funding of medical research into improved treatments has been minimal; according to the NCRI, just over £22m was spent overall on novel prostate cancer research in the UK in 2018. By way of comparison, £40–£46m has been spent on early stage breast cancer research over the last five years and mortality rates have fallen by 18% since 2014.
This is where PCR comes in. We are here to invest in the science, research and medical breakthroughs of the future, and to empower patients and their families to access the right information, have the right conversations, and get the best treatment for them.